-
Product Insights
Metastatic Ovarian Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Ovarian Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic ovarian cancer results from the spread of ovarian cancer cells beyond the ovaries, commonly reaching the peritoneum, liver, lungs, and lymph nodes. Symptoms like abdominal pain, weight loss, and digestive changes may manifest. Diagnosis involves imaging, blood tests, and surgical biopsy. Staging determines treatment strategies, typically involving surgery and chemotherapy. Prognosis varies, influenced by factors such as metastatic extent and...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Each year in the US, more than 19,700 women receive a new diagnosis of ovarian cancer. Â The following are some of the key highlights of the ovarian cancer market: Report deliverables include a PowerPoint report...
-
Sector Analysis
Ovarian Cancer - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional ovarian cancer therapies was $3.2B in 2021. The increasing number of ovarian cancer cases will drive market growth during the forecast period. Ovarian Cancer–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Ovarian Cancer–Cell and Gene Therapies 15-Market Forecast Download a Free Report Sample The ovarian cancer–cell and gene therapies...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.